Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income (2016 - 2025)

Historic Net Income for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$22.6 million.

  • Vanda Pharmaceuticals' Net Income fell 32422.99% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.2 million, marking a year-over-year decrease of 41384.87%. This contributed to the annual value of -$18.9 million for FY2024, which is 85328.82% down from last year.
  • Vanda Pharmaceuticals' Net Income amounted to -$22.6 million in Q3 2025, which was down 32422.99% from -$27.2 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Net Income ranged from a high of $9.6 million in Q2 2021 and a low of -$29.5 million during Q1 2025
  • Over the past 5 years, Vanda Pharmaceuticals' median Net Income value was $180000.0 (recorded in 2023), while the average stood at -$3.0 million.
  • Its Net Income has fluctuated over the past 5 years, first soared by 185646.26% in 2021, then plummeted by 305777.78% in 2024.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Net Income stood at $7.1 million in 2021, then dropped by 2.96% to $6.9 million in 2022, then crashed by 134.71% to -$2.4 million in 2023, then crashed by 105.44% to -$4.9 million in 2024, then plummeted by 359.81% to -$22.6 million in 2025.
  • Its Net Income stands at -$22.6 million for Q3 2025, versus -$27.2 million for Q2 2025 and -$29.5 million for Q1 2025.